Phaseline

Companies › Novelty Nobility

Novelty Nobility: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NN3201
anti-c-Kit antibody-drug conjugate with MMAE payload
KITPhase 1Gastrointestinal Stromal TumorsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06805825NN3201Phase 1Gastrointestinal Stromal TumorsOncologyAug 2027

Targets

KIT (1)

Companies with the same targets

Blueprint Medicines Chia Tai Tianqing Pharmaceutical Group Deciphera Pharmaceuticals Daiichi Sankyo Novartis Exelixis Ono Pharmaceutical Bayer Gossamer Bio USA Etnova Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.